CABA
Price
$1.50
Change
-$0.00 (-0.00%)
Updated
Aug 28 closing price
Capitalization
137.2M
75 days until earnings call
ENTO
Price
$2.15
Change
+$0.24 (+12.57%)
Updated
Aug 28 closing price
Capitalization
3.42M
Interact to see
Advertisement

CABA vs ENTO

Header iconCABA vs ENTO Comparison
Open Charts CABA vs ENTOBanner chart's image
Cabaletta Bio
Price$1.50
Change-$0.00 (-0.00%)
Volume$867.6K
Capitalization137.2M
Entero Therapeutics
Price$2.15
Change+$0.24 (+12.57%)
Volume$274.36K
Capitalization3.42M
CABA vs ENTO Comparison Chart in %
Loading...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CABA vs. ENTO commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and ENTO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CABA: $1.50 vs. ENTO: $2.15)
Brand notoriety: CABA and ENTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 59% vs. ENTO: 11%
Market capitalization -- CABA: $137.2M vs. ENTO: $3.42M
CABA [@Biotechnology] is valued at $137.2M. ENTO’s [@Biotechnology] market capitalization is $3.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green whileENTO’s FA Score has 1 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • ENTO’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTO is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 4 TA indicator(s) are bullish while ENTO’s TA Score has 5 bullish TA indicator(s).

  • CABA’s TA Score: 4 bullish, 6 bearish.
  • ENTO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENTO is a better buy in the short-term than CABA.

Price Growth

CABA (@Biotechnology) experienced а -6.25% price change this week, while ENTO (@Biotechnology) price change was +5.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.14%. For the same industry, the average monthly price growth was +15.09%, and the average quarterly price growth was +29.14%.

Reported Earning Dates

CABA is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (-1.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CABA($137M) has a higher market cap than ENTO($3.42M). ENTO YTD gains are higher at: 15.220 vs. CABA (-33.921). ENTO has higher annual earnings (EBITDA): -4.66M vs. CABA (-140.83M). CABA has more cash in the bank: 195M vs. ENTO (11.4M). ENTO has less debt than CABA: ENTO (836K) vs CABA (24.9M). CABA (0) and ENTO (0) have equivalent revenues.
CABAENTOCABA / ENTO
Capitalization137M3.42M4,012%
EBITDA-140.83M-4.66M3,020%
Gain YTD-33.92115.220-223%
P/E RatioN/A0.03-
Revenue00-
Total Cash195M11.4M1,711%
Total Debt24.9M836K2,978%
FUNDAMENTALS RATINGS
CABA vs ENTO: Fundamental Ratings
CABA
ENTO
OUTLOOK RATING
1..100
7438
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8837
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTO's Valuation (9) in the null industry is in the same range as CABA (12). This means that ENTO’s stock grew similarly to CABA’s over the last 12 months.

ENTO's Profit vs Risk Rating (100) in the null industry is in the same range as CABA (100). This means that ENTO’s stock grew similarly to CABA’s over the last 12 months.

ENTO's SMR Rating (100) in the null industry is in the same range as CABA (100). This means that ENTO’s stock grew similarly to CABA’s over the last 12 months.

ENTO's Price Growth Rating (37) in the null industry is somewhat better than the same rating for CABA (88). This means that ENTO’s stock grew somewhat faster than CABA’s over the last 12 months.

ENTO's P/E Growth Rating (100) in the null industry is in the same range as CABA (100). This means that ENTO’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CABAENTO
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
87%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSPR0.470.02
+4.19%
MSP Recovery Inc
APLT0.510.01
+1.51%
Applied Therapeutics
AFG136.580.49
+0.36%
American Financial Group
WOW5.09N/A
N/A
WideOpenWest
MESO15.95-0.17
-1.05%
Mesoblast Limited

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with IPSC. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then IPSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
N/A
IPSC - CABA
52%
Loosely correlated
-2.91%
ARWR - CABA
48%
Loosely correlated
+2.52%
GBIO - CABA
47%
Loosely correlated
-2.83%
KYTX - CABA
45%
Loosely correlated
+0.27%
ARCT - CABA
45%
Loosely correlated
+0.06%
More

ENTO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTO has been loosely correlated with IVVD. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTO jumps, then IVVD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTO
1D Price
Change %
ENTO100%
+12.57%
IVVD - ENTO
60%
Loosely correlated
+13.66%
FBLG - ENTO
39%
Loosely correlated
+3.40%
RLMD - ENTO
35%
Loosely correlated
+15.76%
NEVPF - ENTO
31%
Poorly correlated
N/A
CABA - ENTO
31%
Poorly correlated
N/A
More